Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared on X:
“SOFT/TEXT at 15 Years
One size does not fit all. Exemestane + OFS should be prioritized for high-risk premenopausal HR+/HER2 breast cancer, while treatment de-escalation remains reasonable for lower risk disease.”
Title: Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer
Authors: P. A. Francis, O. Pagani, G. F. Fleming, B. A. Walley, M. Colleoni, G. Rubovszky, C. Tondini, E. M. Ciruelos, H. L. Gomez, H. R. Bonnefoi, H. J. Burstein, C. Chini, F. Puglisi, S. Spazzapan, A. Bernardo, M. A. Climent, M. Bellet, T. Ruhstaller, B. Bermejo, S. K. L. Chia, S. Martino, C. E. Geyer, M. P. Goetz, J. N. Ingle, V. Stearns, N. E. Davidson, F. Le Du, B. Müller, R. E. Coleman, S. Loibl, E. P. Winer, B. Ruepp, S. Loi, I. Láng, A. S. Coates, R. D. Gelber, A. Goldhirsch, M. M. Regan
Read the full article.
You can also read:
